antibody-drug conjugate izalontamab brengitecan improves survival in advanced food pipe cancer
- antibody-drug conjugate izalontamab brengitecan improves survival in advanced food pipe cancer
- Targeted drugs show activity against metastatic eye melanoma
- Perioperative camrelizumab plus chemotherapy improved outcomes in head and neck cancer
- Immunotherapy plus chemotherapy improved event-free survival in pancreatic cancer
- Cancer society updates prostate cancer screening advice
- Survey found gaps in lymphoma care across Latin America
- Children’s cancer survival reached 90% in 2017, but gaps remain
antibody-drug conjugate izalontamab brengitecan improves survival in advanced food pipe cancer
In a China-based trial of 497 people with recurrent or metastatic food pipe cancer after first-line treatment, people lived 9.79 months with antibody-drug conjugate izalontamab brengitecan versus 7.20 months with chemotherapy. Severe treatment-related side effects were more common with the antibody-drug conjugate.
“These findings support izalontamab brengitecan as a new second-line treatment for this population in China.”
Why it matters. People whose advanced food pipe cancer grows after first treatment may have another option that helped them live longer. Results from a large final-stage trial like this decide approvals.
JAMA, 12 Nov 2026 · Phase III human clinical trial | 704 patients Worth sharing · Share on X · Email a friendTargeted drugs show activity against metastatic eye melanoma
In a phase II trial, 44 people with untreated metastatic eye melanoma received the targeted drugs darovasertib and crizotinib. The tumors shrank in 34.1% of patients.
Why it matters. People with metastatic eye melanoma may have another targeted treatment option. A larger trial usually comes before approval.
The ASCO Post, 12 Nov 2026 · Phase II human clinical trial Worth sharing · Share on X · Email a friendPerioperative camrelizumab plus chemotherapy improved outcomes in head and neck cancer
In a phase 2 trial, 125 people with operable, locally advanced head and neck cancer received surgery-based treatment, with or without immunotherapy camrelizumab plus chemotherapy before surgery and camrelizumab afterward. At two years, 77.8% in the added-treatment group were event-free, compared with 46.1% in the control group.
Why it matters. People with operable, locally advanced head and neck cancer may have more time without cancer-related events with treatment before and after surgery. A larger trial usually comes before approval.
JAMA Oncology, 12 Nov 2026 · Phase II human clinical trial | 125 patients Worth sharing · Share on X · Email a friendImmunotherapy plus chemotherapy improved event-free survival in pancreatic cancer
In a phase II trial, 392 people with borderline resectable or locally advanced pancreatic cancer received chemotherapy with or without the immunotherapy toripalimab. Time before an event was 11.1 months with the combination and 9.6 months with chemotherapy alone.
Why it matters. People with borderline resectable pancreatic cancer may have more time before an event when immunotherapy is added to chemotherapy. A larger trial usually comes before approval.
The ASCO Post, 12 Nov 2026 · Phase II human clinical trial | 392 patients Worth sharing · Share on X · Email a friendCancer society updates prostate cancer screening advice
The American Cancer Society recommends a prostate-specific antigen test every 2 years for average-risk men aged 50 to 69, and annual testing from age 45 for Black men and those with a strong family history. The guideline says screening reduces prostate cancer deaths and advanced diagnoses.
Why it matters. Men at higher risk may start screening earlier, while follow-up tests can help avoid unnecessary treatment. This is official guidance for doctors.
The ASCO Post, 12 Nov 2026 · Clinical practice guideline | 333,830 menSurvey found gaps in lymphoma care across Latin America
A survey of cancer centers in Latin America found limited access to advanced tests and treatments for lymphoma. Commercial CAR-T therapy was available at 5% of centers.
“Our findings highlight striking disparities between guideline-recommended lymphoma care and real-world institutional capacity across LATAM, underscoring the importance of collaborative efforts in building capacity and advocating for equitable access.”
Why it matters. People with lymphoma in Latin America could benefit if centers gain better access to advanced tests and treatments. It studied patient records rather than testing a treatment.
JCO Global Oncology, 12 Nov 2026 · Human observational studyChildren’s cancer survival reached 90% in 2017, but gaps remain
Researchers reviewed records for children diagnosed with cancer in the United States from 1975 to 2022. Five-year survival rose from 60% in 1975 to 90% in 2017, but disparities by race and ethnicity persisted.
“Our findings, however, also point to where children and families still need us to do better.” Researchers looked at survival trends for children and adolescents with cancer in the United States between 1975 and 2022 to update outcome statistics and highlight disparities in trends to help guide future research.”
Why it matters. More children with cancer may live longer, though survival gains have not reached all racial and ethnic groups equally. It studied patient records rather than testing a treatment.
The ASCO Post, 12 Nov 2026 · Human observational study | 152,275 childrenDeals and stopped trials
- Phase 1b/2 to Evaluate the Safety, Tolerability, and Efficacy of TXN10128 in Combination With TOPO-I Inhibitor-based Therapies (Irinotecan or TROP2 antibody-drug conjugate) in Advanced or Metastatic EGFR Mutated non-small cell lung cancerPhase I/II · Txinno Bioscience Inc. · earlier phase I: NCT05978492
India
New trials
- Phase 1b/2 to Evaluate the Safety, Tolerability, and Efficacy of TXN10128 in Combination With TOPO-I Inhibitor-based Therapies (Irinotecan or TROP2 antibody-drug conjugate) in Advanced or Metastatic EGFR Mutated non-small cell lung cancerAntibody-drug conjugates · Phase I/II · 104 people · Txinno Bioscience Inc. · South Korea
- Disulfiram for Preventing Treatment Complications in Patients Undergoing CAR T-cell Therapy for Relapsed or Refractory Diffuse Large B-cell LymphomaCell and gene therapy · Phase I/II · 12 people · University of Michigan Rogel Cancer Center · United States
Worth watching
- Targeted drugs show activity in metastatic eye melanomaAmong 44 people with untreated metastatic uveal melanoma, the protein kinase C inhibitor darovasertib plus the MET inhibitor crizotinib shrank tumors in 34.1%. Median time before the cancer grew was 7.0 months.
- Perioperative camrelizumab treatment improved outcomes in head and neck cancerIn a phase 2 trial, people with resectable head and neck cancer received camrelizumab and chemotherapy before surgery, then camrelizumab after surgery. At two years, 77.8% had lived without cancer returning or worsening, compared with 46.1% after standard surgery-based care.
- Early nutrition supplements reduced weight loss during treatment for nasopharyngeal cancerIn a trial of 216 people with nasopharyngeal cancer receiving chemoradiotherapy, starting oral nutrition supplements at treatment onset reduced weight loss of more than 5%: 65.4% lost that much, compared with 80.7% who started later. Severe mouth sores were also less common.
- Perivascular epithelial remodeling is reflected in circulating cfDNA methylation signals as detection markers for early esophageal tumorigenesisResearch finding, Cancer Discovery, 12 Nov 2026
- Second Cancer Risk in Female Survivors of Hodgkin Lymphoma: A National Cohort Analysis Across Treatment ErasResearch finding, Journal of Clinical Oncology, 12 Nov 2026
- Genomic Atlas Reveals Where Dog and Human Cancers DivergeResearch finding, Cancer Discovery, 12 Nov 2026